Was Friday The 13th SHINING or DARK for These 5 Stocks?

JPMorgan Chase (NYSE:JPM) shares closed nearly 6 percent higher on Friday. America’s largest bank by assets reported a pretax loss from the “London Whale” chief investment office of $4.4 billion, lower than the $5 billion to $7 billion whisper number. Second-quarter earnings came in at $1.21 per share, compared to $1.27 a year earlier. However, JPMorgan Chase will restate its first quarter numbers from its CIO trading losses and cut net income by $459 million.

A Closer Look: JPMorgan Earnings Cheat Sheet>>

Facebook (NASDAQ:FB) shares finished the week on a quiet note. The social-media giant closed 0.29 percent lower Friday, as a recent BBC report suggests companies are wasting money on Facebook advertisements that are meant to gain “likes” from members.

Wells Fargo (NYSE:WFC) also received a boost from earnings Friday. The nation’s largest mortgage lender reported second-quarter earnings of 82 cents per share, compared to 70 cents per share a year earlier. “Wells Fargo’s strong financial results this quarter again reflect the benefit of our diversified business model,” Chief Executive John Stumpf said in a statement. However, expenses totaled $12.4 billion and the bank said it would not meet its goal of reducing costs to $11.25 billion by the fourth-quarter.

Don’t Miss: Why are These Companies Betting BIG on AMERICA?

Friday the 13th was unlucky for Lexmark International (NYSE:LXK). Shares finished Friday down 16.25 percent, representing fresh multi-year lows. Due to weaker-than-expected demand in Europe, the company reduced its second-quarter earnings outlook to 53-55 cents, down from 65-75 cents per share. The company explained, “This revised second quarter outlook reflects a weaker than expected demand environment, particularly in Europe, and a larger than expected impact from unfavorable changes in currency exchange rates.”

Despite the broad market rally, Vivus Inc. (NASDAQ:VVUS) shares declined 2.06 percent on Friday. The company remains in focus ahead of a highly-watched decision. On July 17, Vivus awaits word from the FDA on its diet pill Qnexa. The approval decision was originally expected in April, but was delayed until next week. If approved, it would become the second weight-loss pill to be approved by the FDA this year. Last month, Arena Pharmaceutical (NASDAQ:ARNA) won approval for its Lorcaserin drug that affects an area of the brain that helps people eat less and feel full after eating only small amounts of food.

Investor Insight: SHOWDOWN: Apple Store vs Microsoft Store